Browse By: Country ι Category ι Publisher ι Tag
Home  »  Current Partnering

Current Partnering Market Research Reports

Current Partnering: The source of best practice for dealmakers

Current Partnering is the leading publisher of partnering deal terms and best practice for dealmakers. Report titles cover all aspects of partnering best practice and deal terms, providing users with the information and insight required to optimise their partnering activities. 



Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
The Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies.   The report provides a detailed understand and analysis of how and why companies enter option and evaluation deals. The majority of deals are multicomponent whereby the licensor offers a right to option and evaluation the resultant product of the research collaboration. There are also numerous pure option and evaluation deals whereby the products originator takes on a partner in order to maximize a products presence in the marketplace.   Understanding the flexibility of a prospective partner’s n
Published Date: Nov 2014
Published By: Current Partnering

Price: $2995
Pharmacogenomics Partnering Terms and Agreements
The Pharmacogenomics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pharmacogenomics partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation proces
Published Date: Nov 2014
Published By: Current Partnering

Price: $1995
Personalized Medicine Partnering Terms and Agreements
Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.   The Personalized Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collabor
Published Date: Nov 2014
Published By: Current Partnering

Price: $3295
Biomarker Partnering Terms and Agreements
The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in biomarker partnering deals Biomarker partnering agreement structure Biomarker partnering contract documents Top biomarker deals by value Most active biomarker dealmakers   The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of
Published Date: Nov 2014
Published By: Current Partnering

Price: $2995
Companion Diagnostics Partnering Terms & Agreements
The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight in
Published Date: Nov 2014
Published By: Current Partnering

Price: $1995
Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics
The Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies.   This new 1st edition, includes:   Trends in joint venture deals Joint venture agreement structure Joint venture contract documents Top joint venture deals by value Most active joint venture dealmakers Comprehensive directory of joint venture deals since 2009   This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.   The report provides details of joint venture agreements from 2009 to end of August 2014.   The report pr
Published Date: Oct 2014
Published By: Current Partnering

Price: $1995
Molecular Diagnostics Partnering Terms and Agreements
The Molecular Diagnostics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.     This report provides details of the latest molecular diagnostics agreements announced in the healthcare sectors.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - co
Published Date: Oct 2014
Published By: Current Partnering

Price: $1995
Regenerative Medicine Partnering Terms and Agreements
The Regenerative Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in regenerative medicine  Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for regenerative medicine and stem cells   The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtain
Published Date: Oct 2014
Published By: Current Partnering

Price: $2995
Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you ca
Published Date: Sep 2014
Published By: Current Partnering

Price: $3295
Discovery Stage Partnering Terms and Agreements in Pharma and Biotech
The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you
Published Date: Sep 2014
Published By: Current Partnering

Price: $3295
Jazz Pharmaceuticals Partnering 2009-2014
The Partnering Agreements with Jazz Pharmaceuticals 2009-2014 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.   This report provides all the information you require to better understand Jazz Pharmaceuticals and its partnering interests and activities over the past seven years.   On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.   The report will be delivered in PDF format within 3 working days of receipt of order. If CD-Rom version purchased, the report will be sent by courier using express service.   One of the key aspects of partnering is finding those companies that are potential partners for the development
Published Date: Sep 2014
Published By: Current Partnering

Price: $995
Salix Pharmaceuticals Partnering 2009-2014
The Partnering Agreements with Salix Pharmaceuticals 2009-2014 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.   This report provides all the information you require to better understand Salix Pharmaceuticals and its partnering interests and activities over the past five years.   On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.   The report will be delivered in PDF format within 3 working days of receipt of order. If CD-Rom version purchased, the report will be sent by courier using express service.   One of the key aspects of partnering is finding those companies that are potential partners for the developmen
Published Date: Sep 2014
Published By: Current Partnering

Price: $995
Pharmacyclics Partnering 2009-2014
The Partnering Agreements with Pharmacyclics 2009-2014 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.   This report provides all the information you require to better understand Pharmacyclics and its partnering interests and activities over the past five years.   On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.   The report will be delivered in PDF format within 3 working days of receipt of order. If CD-Rom version purchased, the report will be sent by courier using express service.   One of the key aspects of partnering is finding those companies that are potential partners for the development and commercial
Published Date: Sep 2014
Published By: Current Partnering

Price: $995
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.   This report provides details of the latest preclinical agreements announced in the healthcare sector.   Understanding the flexibility of a prospective
Published Date: Sep 2014
Published By: Current Partnering

Price: $3295
Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics
The Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.   The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract docum
Published Date: Aug 2014
Published By: Current Partnering

Price: $2995
Co-development Terms & Agreements in Pharma, Biotech and Diagnostics
The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies.   The report provides a detailed understand and analysis of how and why companies enter co-development deals.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this ins
Published Date: Aug 2014
Published By: Current Partnering

Price: $2995
Diagnostic Imaging Partnering Terms and Agreements
The Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter diagnostic imaging partnering deals.  This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:   Imaging CT Endoscope Molecular and nuclear PET SPECT MRI Ultrasound X ray Angiography Fluoroscopy Mammography   This report provides an overview of diagnostic imaging dealmaking, the common clauses, rights and options in the partnering agreement, and also a comprehensive review o
Published Date: Aug 2014
Published By: Current Partnering

Price: $2995
Injectable Drug Delivery Partnering 2009-2014
Injectable Drug Delivery Partnering 2009-2014 report provides understanding and access to the injectable drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in injectable drug delivery partnering deals Top injectable drug delivery deals by value Deals listed by company A-Z, deal type, stage of development, therapy type   Injectable Drug Delivery Partnering 2009-2014 provides understanding and access to the injectable drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter injectable drug delivery partnering deals. The majority of deals are discovery or development stag
Published Date: Aug 2014
Published By: Current Partnering

Price: $995
Transdermal Drug Delivery Partnering 2009-2014
Transdermal Drug Delivery Partnering 2009-2014 report provides understanding and access to the transdermal drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.   Trends in transdermal drug delivery partnering deals Top transdermal drug delivery deals by value Deals listed by company A-Z, deal type, stage of development, therapy type   Transdermal Drug Delivery Partnering 2009-2014 provides understanding and access to the transdermal drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter transdermal drug delivery partnering deals. The majority of deals are discover
Published Date: Aug 2014
Published By: Current Partnering

Price: $995
Topical Drug Delivery Partnering 2009-2014
Topical Drug Delivery Partnering 2009-2014 report provides understanding and access to the topical drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.   Trends in topical drug delivery partnering deals Top topical drug delivery deals by value Deals listed by company A-Z, deal type, stage of development, therapy type   Topical Drug Delivery Partnering 2009-2014 provides understanding and access to the topical drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter topical drug delivery partnering deals. The majority of deals are discovery or development stage where
Published Date: Aug 2014
Published By: Current Partnering

Price: $995
Targeted Drug Delivery Partnering 2009-2014
Targeted Drug Delivery Partnering 2009-2014 report provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.   Trends in targeted drug delivery partnering deals Top Targeted deals by value Deals listed by company A-Z, deal type, stage of development, therapy type   Targeted Drug Delivery Partnering 2009-2014 provides understanding and access to the targeted partnering deals and agreements entered into by the world’s leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter targeted drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtai
Published Date: Aug 2014
Published By: Current Partnering

Price: $995
Personalized Medicine in Oncology Partnering Terms and Agreements
The Personalized Medicine in Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the n
Published Date: Aug 2014
Published By: Current Partnering

Price: $2995
Monoclonal Antibodies Partnering Terms and Agreements
The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment
Published Date: Aug 2014
Published By: Current Partnering

Price: $2995
Trends in Therapeutic Partnering
The Trends in Therapeutic Partnering report provides the most comprehensive and in-depth insight into the 35 most popular therapeutic targets for partnering in the period 2009 to mid 2014. The report provides a detailed understanding and analysis of the most popular therapeutic targets for partnering in the period 2009 to mid 2014. The majority of deals are discovery, preclinical and clinical stage whereby the licensee obtains a right or an option right to license or access the licensors compounds or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next gener
Published Date: Aug 2014
Published By: Current Partnering

Price: $3995
Cancer Monoclonal Antibody Partnering Terms and Agreements
The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer monoclonal antibody partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer monoclonal antibody partnering contract documents Top cancer monoclonal antibody deals by value The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an understanding and analysis of how and why companies enter cancer monoclonal
Published Date: Aug 2014
Published By: Current Partnering

Price: $1995
Drug Delivery Partnering Terms and Agreements
The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of
Published Date: Jul 2014
Published By: Current Partnering

Price: $3295
Diagnostics Partnering Terms and Agreements
The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can
Published Date: Jul 2014
Published By: Current Partnering

Price: $3295
Vaccine Partnering Terms and Agreements
The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in vaccine and adjuvant partnering deals Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for vaccines   The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative
Published Date: Jul 2014
Published By: Current Partnering

Price: $2995
Licensing Terms and Agreements in Pharma, Biotech and Diagnostics
The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies. The report provides a detailed understand and analysis of how and why companies enter licensing deals. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases
Published Date: Jul 2014
Published By: Current Partnering

Price: $3295
Partnering Agreements with Sun Pharmaceutical 2009-2014
The Partnering Agreements with Sun pharmaceutical 2009-2014 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.   This report provides all the information you require to better understand Sun pharmaceutical and its partnering interests and activities over the past seven years.   On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.   The report will be delivered in PDF format within 3 working days of receipt of order. If CD-Rom version purchased, the report will be sent by courier using express service.   One of the key aspects of partnering is finding those companies that are potential partners for the development and
Published Date: Apr 2014
Published By: Current Partnering

Price: $995
Partnering Deals and Alliances with Big Pharma
The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.   Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:   Detailed partnering activity profiles for each of the top 50 big pharma companies Over 300 charts showing a company’s dealmaking activity since 2007, allowing quick identification potential partners Partnering therapy focus revealed Partnering activity since 2009 – number of deals per year Full listing of partnering deals Activity by deal type Activity by industry sector Activity by phase of development Activity by technology type Activity by th
Published Date: Mar 2014
Published By: Current Partnering

Price: $3295
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter discovery, preclinical and clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.   Understanding the flexibility of a prospective partner’s negotiated deals terms pro
Published Date: Mar 2014
Published By: Current Partnering

Price: $5495
Partnering Deals and Alliances with Big Biotech
The Partnering Deals and Alliances with Big Biotech report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.   Partnering Deals and Alliances with Big Biotech provides the user with the following key benefits:   Detailed partnering activity profiles for each of the top 50 big biotech companies Over 300 charts showing a company’s dealmaking activity since 2009, allowing quick identification potential partners Partnering therapy focus revealed Partnering activity since 2009 – number of deals per year Full listing of partnering deals Activity by deal type Activity by industry sector Activity by phase of development Activity by technology type Activity by th
Published Date: Mar 2014
Published By: Current Partnering

Price: $2195
Obstetrics Partnering Terms and Agreements
The Obstetrics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the obstetrics partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter obstetrics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors obstetrics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can e
Published Date: Feb 2014
Published By: Current Partnering

Price: $1995
Bigpharma Deals and Alliances of 2013
The Bigpharma Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013.   Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.   The initial chapters of this report provide an orientation of 2013’s dealmaking and business activities.   Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication.   Chapter 2 provides a review of the leading
Published Date: Feb 2014
Published By: Current Partnering

Price: $1495
Pharmaceutical Deals and Alliances of 2013
The Pharmaceutical Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013.   Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.   The initial chapters of this report provide an orientation of 2013’s dealmaking and business activities.   Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication.   Chapter 2 provides a review of the lea
Published Date: Feb 2014
Published By: Current Partnering

Price: $1495
Biotechnology Deals and Alliances of 2013
The Biotechnology Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013.   Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.   The initial chapters of this report provide an orientation of 2013’s dealmaking and business activities.   Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication.   Chapter 2 provides a review of the lead
Published Date: Feb 2014
Published By: Current Partnering

Price: $1495
Merger and Acquisition Deals and Alliances of 2013
The Merger and Acquisition Deals and Alliances of 2013 provides comprehensive understanding and unprecedented access to the M&A deals and agreements entered into by the worlds leading healthcare companies during 2013.   Using these reports, dealmakers will effectively and efficiently gain insight into the M&A activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.   The initial chapters of this report provide an orientation of 2013’s M&A dealmaking and business activities.   Chapter 1 provides an overview of the trends in M&A dealmaking during 2013.   Chapter 2 provides a review of the leading M&A deals during 2013. Deals are listed by headline value, signed by bigpha
Published Date: Feb 2014
Published By: Current Partnering

Price: $1495
Big Biotech Deals and Alliances of 2013
A review of big biotech partnering trends and comprehensive directory of deals and alliances announced during 2013.   Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.   The initial chapters of this report provide an orientation of 2013’s dealmaking and business activities.   Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication.   Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by bigbiotech, and most active bigbiotech
Published Date: Feb 2014
Published By: Current Partnering

Price: $1495
Dermatology Partnering Terms and Agreements
The Dermatology Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter dermatology partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors dermatology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.   This report provides details of the latest dermatology deals and contracts announced in the healthcare sectors.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms.
Published Date: Feb 2014
Published By: Current Partnering

Price: $2995
Infectious Vaccines Partnering Terms and Agreements
The Infectious Vaccines Partnering Terms and agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.  The report also includes adjuvant deals and alliances.   This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect
Published Date: Dec 2013
Published By: Current Partnering

Price: $1995
Distribution partnering Terms and Agreements in Pharma, Biotech and Diagnostics
The Distribution Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma companies.   The report provides a detailed understand and analysis of how and why companies enter distribution deals.   The majority of deals are multicomponent whereby the licensor offers a right to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotia
Published Date: Dec 2013
Published By: Current Partnering

Price: $2995
Antibiotics Partnering Terms and Agreements
The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in antibiotics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Antibiotics partnering contract documents Top antibiotics deals by value   The Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby
Published Date: Dec 2013
Published By: Current Partnering

Price: $1995
Antibody Partnering Terms and Agreements
The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.   This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:   Antibodies Antibody-drug conjugates Monoclonal a
Published Date: Dec 2013
Published By: Current Partnering

Price: $2995
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies.   Revised and updated 9th edition, includes:   Trends in co-promotion and co-marketing deals Co-promotion and co-marketing agreement structure Co-promotion and co-marketing contract documents Top
Published Date: Nov 2013
Published By: Current Partnering

Price: $2995
Cancer Vaccine Partnering Terms and Agreements
The Cancer Vaccine Partnering Agreements Terms and Agreements report provides comprehensive understanding and unprecedented access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in cancer vaccine partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer vaccine partnering contract documents Top cancer vaccine deals by value  The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and
Published Date: Nov 2013
Published By: Current Partnering

Price: $1995
Cancer Symptoms Partnering 2007-2013
The Cancer Symptoms Partnering 2007-2013 report provides understanding and access to the cancer symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in solid tumor cancer partnering deals Top solid tumor cancer deals by value Deals listed by company A-Z, industry sector, stage of development, technology type   The Solid Tumor Cancer Partnering 2007-2013 provides understanding and access to the solid tumor cancer partnering deals and agreements entered into by the worlds leading healthcare companies.   This report provides details of thelatest cancer symptoms agreements announced in the healthcare sectors, covering:   Symptoms Oral mucositis Cancer pain Bone Neuropathic Muscular Lymphoedema
Published Date: Oct 2013
Published By: Current Partnering

Price: $995
Acute and Chronic Myelogenous Leukemia Partnering 2007-2013
The Acute and Chronic Myelogenous Leukemia Partnering 2007-2013 report provides understanding and access to the cancer symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in acute and chronic myelogenous leukemia partnering deals Top acute and chronic myelogenous leukemia deals by value Deals listed by company A-Z, industry sector, stage of development, technology type   The Acute and Chronic Myelogenous Leukemia Partnering 2007-2013 provides understanding and access to the acute and chronic myelogenous leukemia partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides an analysis of cancer symptoms partnering deals. The majority of deals are discover
Published Date: Oct 2013
Published By: Current Partnering

Price: $995
Tuberculosis Partnering 2007-2013
The Tuberculosis Partnering 2007-2013 report provides understanding and access to the tuberculosis partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in tuberculosis partnering deals Top tuberculosis deals by value Deals listed by company A-Z, industry sector, stage of development, technology type   The Tuberculosis Partnering 2007-2013 provides understanding and access to the tuberculosis partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides an analysis of tuberculosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors tuberculosis technology. These
Published Date: Oct 2013
Published By: Current Partnering

Price: $995
Practical Guide to Finding Partners
Current Partnering’s Practical Guide to Finding Partners provides a comprehensive overview of all the steps required to identify and secure potential partnering opportunities either for an in-licensing or out-licensing activity. The report takes the reader through the practical steps required to prepare for partnering, prepare supporting materials, identify and shortlist potential partners and opportunities, identifying and contacting the right person in the partner company, and managing of discussions through to deal negotiation. In addition, the report provides a detailed overview of the activities a business development executive and a company should be undertaking to build and maintain an extensive contact network, and to become partner of choice, respectively. The r
Published Date: Sep 2013
Published By: Current Partnering

Price: $1295
Bioinformatics Partnering Terms and Agreements
The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access tthe bioinformatics partnering deals and agreements entered intby the worlds leading healthcare companies. Trends in bioinformatics partnering deals Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for bioinformatics The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access tthe bioinformatics partnering deals and agreements entered intby the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering d
Published Date: Sep 2013
Published By: Current Partnering

Price: $2995
Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
The Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter royalty financing deals.   Comprehensive directory of royalty financing deals since 2009 Royalty financing contract documents Royalty financing agreement terms Royalty financing agreement structure Top royalty financing deals by value Most active Royalty financing dealmakers   The Royalty Financing Terms and Agreements report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies.   The report provides a detailed understand and analysis of how and why companies enter royalty financing partnering de
Published Date: Aug 2013
Published By: Current Partnering

Price: $2695
Manufacturing and Supply Partnering Terms and Agreements
The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the world’s biopharma companies. The report provides a detailed understand and analysis of how and why companies enter manufacturing and supply deals.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insi
Published Date: Aug 2013
Published By: Current Partnering

Price: $2695
Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics
The Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the asset purchase agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter asset purchase deals.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and
Published Date: Aug 2013
Published By: Current Partnering

Price: $2695
Orphan Drugs Partnering Terms and Agreements
The Orphan Drugs Partnering Terms and Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in orphan drugs partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Orphan drugs partnering contract documents Top orphan drugs deals by value   The OrphanDrugs Partnering Terms and Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides an understanding and analysis of how and why companies enter orphan drugs partnering deals. The majority of deals are discovery or developme
Published Date: Aug 2013
Published By: Current Partnering

Price: $1795
Gene Therapy Partnering Terms and Agreements
The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in gene therapypartnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Gene therapypartnering contract documents Top gene therapy deals by value   The Gene Therapy Partnering Terms and Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter gene therapypartnering deals. The majority of deals are early development stage wher
Published Date: Jul 2013
Published By: Current Partnering

Price: $1795
Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics
The Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals.   Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press
Published Date: Jul 2013
Published By: Current Partnering

Price: $2995
Gilead Sciences Partnering 2005-2013
This report provides all the information you require to better understand Gilead Sciences and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 prov
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
GlaxoSmithKline Partnering 2005-2013
This report provides all the information you require to better understand GlaxoSmithKline and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 prov
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Grifols Partnering 2005-2013
This report provides all the information you require to better understand Grifols and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. 
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Hospira Partnering 2005-2013
This report provides all the information you require to better understand Hospira and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 provides an
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Johnson & Johnson / Janssen Partnering 2005-2013
This report provides all the information you require to better understand Johnson & Johnson and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1&nbs
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Kyowa Hakko Partnering 2005-2013
This report provides all the information you require to better understand Kyowa Hakko Kirin and its partnering interests and activities over the past seven years.  One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business acti
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Lundbeck Partnering 2005-2013
This report provides all the information you require to better understand Lundbeck and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 provides an
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Menarini Partnering 2005-2013
This report provides all the information you require to better understand Menarini and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 provides an
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Merck & Co Partnering 2005-2013
This report provides all the information you require to better understand Merck & Co and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 provi
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Merck KGaA / Merck Serono Partnering 2005-2013
This report provides all the information you require to better understand Merck KGaA and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 provides
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Mitsubishi Tanabe Partnering 2005-2013
This report provides all the information you require to better understand Mitsubishi Tanabe and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 pr
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Mylan Partnering 2005-2013
This report provides all the information you require to better understand Mylan and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 provides an in
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Novartis Partnering 2005-2013
This report provides all the information you require to better understand Novartis and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 provides an
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Novo Nordisk Partnering 2005-2013
This report provides all the information you require to better understand Novo Nordisk and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 provide
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Nycomed Partnering 2005-2013
This report provides all the information you require to better understand Nycomed and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 provides an
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Otsuka Partnering 2005-2013
This report provides all the information you require to better understand Otsuka and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 provides an i
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Pfizer Partnering 2005-2013
This report provides all the information you require to better understand Pfizer and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 provides an i
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Purdue Partnering 2005-2013
This report provides all the information you require to better understand Purdue and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1 provides an i
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Roche Partnering 2005-2013
This report provides all the information you require to better understand Roche and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities.  C
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Sanofi Partnering 2005-2013
This report provides all the information you require to better understand Sanofi and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. 
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Servier Partnering 2005-2013
This report provides all the information you require to better understand Servier and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives. The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Shionogi Partnering 2005-2013
This report provides all the information you require to better understand Shionogi and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. 
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Shire Partnering 2005-2013
This report provides all the information you require to better understand Shire and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives. The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1&n
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Stada Partnering 2005-2013
This report provides all the information you require to better understand Stada and its partnering interests and activities over the past seven years.  One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives. The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapt
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Takeda Partnering 2005-2013
This report provides all the information you require to better understand Takeda and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives. The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1&
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Teva Partnering 2005-2013
This report provides all the information you require to better understand Teva and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives. The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1&nb
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
UCB Partnering 2005-2013
This report provides all the information you require to better understand UCB and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives. The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1&nbs
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Valeant Partnering 2005-2013
This report provides all the information you require to better understand Valeant and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives. The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Warner Chilcott Partnering 2005-2013
This report provides all the information you require to better understand Warner Chilcott and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives. The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  C
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Watson Partnering 2005-2013
This report provides all the information you require to better understand Watson and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives. The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities.  Chapter 1&
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Bladder Cancer Partnering 2007-2013
The Bladder Cancer Partnering 2007-2013 provides understanding and access to the bladder cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of bladder cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bladder cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking detai
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Brain Cancer Partnering 2007-2013
The Brain Cancer Partnering 2007-2013 provides understanding and access to the brain cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of brain cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lymphoma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Breast Cancer Partnering 2007-2013
The Breast Cancer Partnering 2007-2013 provides understanding and access to the breast cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of breast cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors breast cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details o
Published Date: Jul 2013
Published By: Current Partnering

Price: $1795
Cervical Cancer Partnering 2007-2013
The Cervical Cancer Partnering 2007-2013 provides understanding and access to the cervical cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of cervical cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors cervical cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking d
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Colorectal Cancer Partnering 2007-2013
The Colorectal Cancer Partnering 2007-2013 provides understanding and access to the colorectal cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of colorectal cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors colorectal cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be s
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Gastric Cancer Partnering 2007-2013
The Gastric Cancer Partnering 2007-2013 provides understanding and access to the gastric cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of gastric cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors gastric cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking detai
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Head and Neck Cancer Partnering 2007-2013
The Head and Neck Cancer Partnering 2007-2013 provides understanding and access to the head and neck cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of head and neck cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors head and neck cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller compani
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Leukemia Partnering 2007-2013
The Leukemia Partnering 2007-2013 provides understanding and access to the leukemia partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of leukemia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors leukemia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Liver Cancer Partnering 2007-2013
The Liver Cancer Partnering 2007-2013 provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of liver cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors liver cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of th
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Lung Cancer Partnering 2007-2013
The Lung Cancer Partnering 2007-2013 provides understanding and access to the lung cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of lung cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lung cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the pa
Published Date: Jul 2013
Published By: Current Partnering

Price: $1795
Lymphoma Partnering 2007-2013
The Lymphoma Partnering 2007-2013 provides understanding and access to the lymphoma partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of lymphoma partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lymphoma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the de
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Multiple Myeloma Partnering 2007-2013
The Multiple Myeloma Partnering 2007-2013 provides understanding and access to the multiple myeloma partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of multiple myeloma partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors multiple myeloma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeki
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Ovarian Cancer Partnering 2007-2013
The Ovarian Cancer Partnering 2007-2013 provides understanding and access to the ovarian cancer partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of ovarian cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors ovarian cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking detai
Published Date: Jul 2013
Published By: Current Partnering

Price: $995